A/Prof David Pryor

David-Pryor-linac.jpg

SPECIALIST AREAS

Associate Professor David Pryor is the Director of the Radiation Oncology service at the Princess Alexandra Hospital (Ipswich Rd Campus) and a senior Radiation Oncologist specialising in the management of urological cancers, gastrointestinal cancers and bone/soft tissue tumours (sarcomas).

He is the clinical lead for the stereotactic body radiotherapy (SBRT) program at the Princess Alexandra Hospital, implementing SBRT for prostate, liver and kidney cancers.

EDUCATION

Associate Professor Pryor completed his medical degree with honours at the University of Queensland in 2001 and was awarded his fellowship of the Royal Australian and New Zealand College of Radiologists (RANZCR), Faculty of Radiation Oncology, in 2011.

He is an Adjunct Associate Professor with the Queensland University of Technology (QUT) and a Senior Lecturer with the School of Medicine, University of Queensland. Dr Pryor has been an examiner and member of the curriculum development team for the RANZCR Faculty of Radiation Oncology and past director of training for the Ipswich Rd campus.

RESEARCH & PUBLICATIONS

Associate Professor Pryor has an active clinical research program with special interests in precision radiotherapy (including SBRT), its combination with systemic agents and the incorporation of functional imaging to guide radiation treatment and response. He also has a focus on quality improvement through clinical outcome registries and accelerating the implementation of cutting edge research into standard of care practise.

He has been involved in developing and running a number of collaborative, multicentre clinical trials evaluating SBRT in the management of prostate, kidney and liver cancers and is the past chair of the Genitourinary Working Group of the Trans-Tasman Radiation Oncology collaborative trials group (TROG).

AWARDS & MEMBERSHIPS

Associate Professor Pryor is a member of a number of local, state and national scientific advisory and quality improvement committees aimed at improving outcomes for people living with cancer.